A spatially resolved implantable microdevice for multiplexed in situ screening of engineered cellular therapies in solid tumors.
Panikkanvalappil SR, Maloney E, Ahn SW, Martin S, Marlin C, Bhagavatula SK, Jonas O
Polycomb Scaffolding Subunit EED Supports the SCLC Neuroendocrine Identity and EGFR-Mutant LUAD to SCLC Transformation.
Li Y, Laimon YN, Cho H, Vivero M, de Oliveira GR, Seager MD, Delcea A, Savla V, Chen Y, Durmaz YT, Qiu X, Kukreja S, Li R, El Zarif T, Lu W, Van Orden M, Berchuck JE, Bronson RT, Li S, Ji H, Barbie DA, Politi K, Freedman ML, Long HW, Signoretti S, Oser MG
Proteolysis activity mapping and substrate discovery platform for identifying tumor-activated biosensors.
Algov I, Van Heest A, Hopton M, Liang F, Holmes A, Hao L, Zhou X
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.
Merriam P, Morrow JJ, Mazzola E, Solimini NL, Gokhale PC, Chi P, Chen AP, Agulnik M, Burgess M, Schuetze SM, Somaiah N, Van Tine BA, Pollack SM, Tinoco G, Trent J, Wilky BA, Bothwick N, Eschle BK, Nguyen V, Beumer JH, Rastkari N, Jiwani S, Wu PI, Pelosof L, Hemming ML, Shapiro GI, Demetri G, Bernstein B, George S
PTPN2 inhibition unleashes response to STING agonism in head and neck squamous cell cancer.
Li Z, Fu C, Sehgal K, Egloff AM, Thai TC, Monge OA, Chuong CL, Senent Y, Lineberry MS, Eschle BK, Haratani K, Ivanova EV, Campisi M, Mahadevan NR, Quadarella JD, Gedeon PC, Schoenfeld JD, Kono M, Fahey CG, Chayawatto C, Ngo K, Paweletz CP, Gokhale PC, Manguso RT, Uppaluri R, Barbie DA
The SOS1 inhibitor BI 1701963 as monotherapy or in combination with trametinib in patients with KRAS mutation-positive solid tumors.
Jänne PA, Johnson ML, Li J, Pant S, Dünzinger U, Ilia L, Möldner K, Soh JE, Yamamoto N
Multimodal Assessment of Biological Age Following Radiation Therapy Among Patients With Early-Stage NSCLC.
Lee G, Haugg F, Bontempi D, He J, Bitterman DS, Pai S, Guthier C, Fitzgerald KJ, Kozono DE, Kann BH, Aerts HJWL, Mak RH
Face aging rate quantifies change in biological age to predict cancer outcomes.
Haugg F, Lee G, He J, Warrington A, Bontempi D, Bitterman DS, Catalano PJ, Prudente V, Pai S, Guthier C, Kann BH, Aerts HJ, Mak RH
Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced Fusion-Positive Non-Small Cell Lung Cancer.
Besse B, Subbiah V, Curigliano G, Bowles DW, Doebele RC, Mansfield AS, Baik CS, de Lima Lopes G, Paz-Ares L, Taylor MH, Tan DSW, Alonso G, Gadgeel SM, Kalemkerian GP, Ou SI, van der Wekken AJ, Becerra CR, Evangelist M, Griesinger F, Liu SV, Lou Y, Mazières J, Melear JM, Narang M, Saxena A, Thomas M, Wang S, Thomassen A, Lee DH, Kim DW, Gainor JF
Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non-Small Cell Lung Cancer With or Without Brain Metastases: A Secondary Analysis of Randomized Clinical Trials.
Jänne PA, Planchard D, Goto K, Smit EF, de Langen AJ, Goto Y, Ninomiya K, Kubo T, Pérol M, Felip E, Hayashi H, Nakagawa K, Shimizu J, Nagasaka M, Pereira K, Taguchi A, Ali A, Karnoub M, Yonemochi R, Leung D, Li BT
Survival with Osimertinib plus Chemotherapy in -Mutated Advanced NSCLC.
Jänne PA, Planchard D, Kobayashi K, Yang JC, Liu Y, Valdiviezo N, Kim TM, Jiang L, Kagamu H, Yanagitani N, Wang J, Biswas B, Poltoratskiy A, Neron Y, Rojas C, Koubkova L, Escriu C, Ezeife DA, Mann H, Armenteros-Monterroso E, Rukazenkov Y, Lee CK,
Molecular characterization of NUT carcinoma: a report from the NUT carcinoma registry.
Kim JJ, Walton SA, Mahadevan NR, Haradon J, Paoloni F, Paik PK, Chaft JE, Hsu R, Piha-Paul SA, Jänne PA, Barbie DA, Sholl LM, Dubois SG, Hanna GJ, Shapiro GI, French CA, Luo J
